Antimicrobial Resistance (AMR) Epidemiology Forecast 2025-2034

Antimicrobial resistance (AMR) poses a global health crisis, with projections indicating that it can account for nearly 10 million annual deaths by 2050. The rate of occurrence is high in low- and middle-income countries, owing to the substantial burden of infectious diseases, the COVID-19 pandemic, and increased antibiotic use.

Antimicrobial Resistance (AMR) Epidemiology Forecast Report Coverage

The “Antimicrobial Resistance (AMR) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of antimicrobial resistance (AMR). It projects the future incidence and prevalence rates of antimicrobial resistance (AMR) across various populations. The study covers age, gender, and type as major determinants of the antimicrobial resistance (AMR)-affected population. The report highlights patterns in the prevalence of antimicrobial resistance (AMR) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of antimicrobial resistance (AMR) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Antimicrobial Resistance (AMR): Disease Overview

Antimicrobial resistance (AMR) refers to the ability of microorganisms to resist the effects of drugs that once killed them or inhibited their growth. One of the primary causes of antimicrobial resistance is the overuse and misuse of antimicrobial agents (antibiotics, antivirals, antifungals, etc.). AMR infections can lead to longer hospital stays, higher medical costs, and an increase in mortality rates, thus posing a substantial burden on the healthcare system.

Antimicrobial Resistance (AMR): Treatment Overview

The treatment of antimicrobial resistance focuses on managing existing infections and preventing the spread of resistant pathogens. Alternative antibiotics, including newer classes of antibiotics or older ones that may have been underused in recent years, are commonly used. Combination therapy, where two or more antibiotics are used together to treat infections, is another treatment approach. Targeted therapy is a more precise strategy, relying on advanced diagnostic technologies, that is increasingly favored for its positive treatment outcomes.

Epidemiology

The antimicrobial resistance (AMR) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for antimicrobial resistance (AMR) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for antimicrobial resistance (AMR) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The 2022 Global Antimicrobial Resistance and Use Surveillance System (GLASS) report reveals concerning antimicrobial resistance rates globally, with median resistance rates of 42% for third-generation cephalosporin-resistant E. coli and around 35% for methicillin-resistant Staphylococcus aureus across 76 countries.
• It is projected that antimicrobial-resistant infections can lead to about 10 million annual deaths by 2050.
• In 2019, antibiotic resistance was responsible for the death of at least 1.27 million people worldwide and linked to roughly 5 million deaths.
• The incidence of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections in the European Union countries was estimated to be 4.64 per 100,000 population.

Country-wise Antimicrobial Resistance (AMR) Epidemiology

The antimicrobial resistance (AMR) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of antimicrobial resistance (AMR) varies between countries, owing to differences in antibiotic consumption, healthcare infrastructure, and regulatory policies. Several factors such as infection control measures, surveillance systems, and public attitudes also impact the prevalence rate of the infection. In the United States, it is estimated that over 2.8 million antimicrobial-resistant infections occur annually.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of antimicrobial resistance (AMR) based on several factors.
• Antimicrobial Resistance (AMR) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of antimicrobial resistance (AMR) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of antimicrobial resistance (AMR) epidemiology in the 8 major markets?
• What will be the total number of patients with antimicrobial resistance (AMR) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of antimicrobial resistance (AMR) in the 8 major markets in the historical period?
• Which country will have the highest number of antimicrobial resistance (AMR) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of antimicrobial resistance (AMR) during the forecast period of 2025-2034?
• What are the currently available treatments for antimicrobial resistance (AMR)?
• What are the disease risks, signs, symptoms, and unmet needs of antimicrobial resistance (AMR)?

This product will be delivered within 3-5 business days.